Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

143.20EUR
21 Sep 2018
Change (% chg)

€-1.35 (-0.93%)
Prev Close
€144.55
Open
€144.60
Day's High
€145.75
Day's Low
€141.90
Volume
196,543
Avg. Vol
90,007
52-wk High
€155.95
52-wk Low
€97.24

Chart for

About

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes... (more)

Overall

Beta: 0.72
Market Cap(Mil.): €11,999.32
Shares Outstanding(Mil.): 83.79
Dividend: 1.00
Yield (%): 0.70

Financials

  IPN.PA Industry Sector
P/E (TTM): 34.48 30.48 32.69
EPS (TTM): 4.15 -- --
ROI: 15.73 13.04 12.72
ROE: 21.51 14.99 14.85

BRIEF-Ipsen Q1 Sales up at 510.3 Million Euros

* IPSEN REPORTS STRONG Q1 2018 SALES GROWTH OF 23.1% AT CONSTANT EXCHANGE RATES

Apr 26 2018

BRIEF-Ipsen Announces EMA Validation Of Filing Of New Application For Additional Indication For Cabometyx®

* ANNOUNCES EMA VALIDATION OF FILING OF A NEW APPLICATION FOR ADDITIONAL INDICATION FOR CABOMETYX®, FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Mar 28 2018

BRIEF-Ipsen Receives Positive CHMP Opinion For Cabometyx

* IPSEN RECEIVES POSITIVE CHMP OPINION FOR CABOMETYX® (CABOZANTINIB) FOR THE FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR- RISK ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 23 2018

Earnings vs. Estimates